Update on transplant pharmacology: sirolimus.
Rapamune (Sirolimus), the latest immunosuppressant agent for solid organ transplants, is prescribed for induction therapy, refractory rejection, steroid withdrawal, and combination therapy. As the use of this agent increases among various transplant populations, it is essential for critical care nurses to be cognizant of the indications, pharmacodynamics, current research findings, side effects, and implications. This knowledge will ultimately improve patient education and outcomes in this ever-growing field of nursing.
Hoffmann
Rosemary L
RL
University of Pittsburgh School of Nursing, PA 15261, USA. rho100@pitt.edu
Roesch
Tricia
T
D002986:Clinical Trials as Topic; D003422:Critical Care / Q000379:methods; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D016207:Cytokines / Q000145:classification / Q000187:drug effects / Q000276:immunology; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007166:Immunosuppressive Agents / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008657:Metabolic Clearance Rate; D024802:Nurse's Role; D020123:Sirolimus / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology; D014181:Transplantation Immunology / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome
D065607:Cytochrome P-450 Enzyme Inhibitors; D016207:Cytokines; D007166:Immunosuppressive Agents; D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D020123:Sirolimus